Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain. Cantarero D, Ocana D, Onieva-Garcia MA, Rodriguez-Garcia J, et al. Vaccine 2023 Jul 19:S0264-410X(23)00828-9. doi: 10.1016/j.vaccine.2023.

Read + Share

Amedeo Smart

Independent Medical Education

Cantarero D, Ocana D, Onieva-Garcia MA, Rodriguez-Garcia J, et al. Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain. Vaccine 2023 Jul 19:S0264-410X(23)00828-9. doi: 10.1016/j.vaccine.2023.
PMID: 37479615